These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19852718)

  • 1. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Washburn WN
    J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
    [No Abstract]   [Full Text] [Related]  

  • 4. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 6. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
    Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
    Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.
    Pfister M; Whaley JM; Zhang L; List JF
    Clin Pharmacol Ther; 2011 Apr; 89(4):621-5. PubMed ID: 21346749
    [No Abstract]   [Full Text] [Related]  

  • 14. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
    Nat Rev Drug Discov; 2010 Mar; 9(3):182. PubMed ID: 20190779
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
    Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.
    Machado UF; Corrêa-Giannella ML
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):5-9. PubMed ID: 24397354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
    Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.